Ratings by Piper Sandler (Do Kim)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
6/8/2022 Rigel Pharmaceuticals RIGL Downgrade Neutral
(Overweight)
1.76
(1.02)
-42.05% Details
5/19/2022 Replimune Group REPL Maintain Overweight
(N/A)
 
 
  Details
5/17/2022 Scholar Rock SRRK Maintain Overweight
(N/A)
 
 
  Details
5/17/2022 Gilead Sciences GILD Maintain Neutral
(N/A)
 
 
  Details
5/11/2022 AbCellera Biologics ABCL Maintain Overweight
(N/A)
 
 
  Details
5/6/2022 Vertex VRTX Maintain Neutral
(N/A)
 
 
  Details
4/29/2022 Gilead Sciences GILD Maintain Neutral
(N/A)
 
 
  Details
4/22/2022 Vertex VRTX Maintain Neutral
(N/A)
 
 
  Details
4/11/2022 Affimed Therapeutics AFMD Maintain Overweight
(N/A)
 
 
  Details
4/4/2022 Gilead Sciences GILD Maintain Neutral
(N/A)
 
 
  Details
3/31/2022 Affimed Therapeutics AFMD New Coverage Overweight
(N/A)
4.45
(2.71)
-39.1% Details
3/31/2022 Travere Therapeutics TVTX New Coverage Overweight
(N/A)
26.05
(24.19)
-7.14% Details
3/31/2022 Ionis Pharmaceuticals IONS New Coverage Overweight
(N/A)
36.48
(39.25)
7.59% Details
3/31/2022 Codexis, Inc. CDXS New Coverage Overweight
(N/A)
21.18
(11.44)
-45.99% Details
3/22/2022 TCR2 Therapeutics TCRR Maintain Overweight
(N/A)
 
 
  Details
1/24/2022 Schrodinger SDGR Maintain Overweight
(N/A)
 
 
  Details
1/24/2022 Gilead Sciences GILD Maintain Neutral
(N/A)
 
 
  Details
11/19/2021 TCR2 Therapeutics TCRR New Coverage Overweight
(N/A)
6.60
(2.86)
-56.67% Details
11/19/2021 Replimune Group REPL New Coverage Overweight
(N/A)
33.27
(18.52)
-44.33% Details
11/19/2021 Gilead Sciences GILD New Coverage Neutral
(N/A)
67.46
(63.08)
-6.49% Details
11/19/2021 Exelixis EXEL New Coverage Overweight
(N/A)
17.88
(22.22)
24.27% Details
11/19/2021 AbCellera Biologics ABCL New Coverage Overweight
(N/A)
14.82
(10.65)
-28.14% Details
11/19/2021 Vertex VRTX Downgrade Neutral
(Overweight)
188.25
(292.55)
55.41% Details
11/19/2021 Scholar Rock SRRK New Coverage Overweight
(N/A)
34.34
(5.96)
-82.64% Details
11/18/2021 Schrodinger SDGR New Coverage Overweight
(N/A)
44.45
(30.41)
-31.59% Details